Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide

Version 1 : Received: 18 July 2020 / Approved: 20 July 2020 / Online: 20 July 2020 (03:46:11 CEST)

How to cite: Youssef, J.G.; Said, S.; Youssef, G.; Javitt, M.J.; Javitt, J.C. Treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide. Preprints 2020, 2020070453 (doi: 10.20944/preprints202007.0453.v1). Youssef, J.G.; Said, S.; Youssef, G.; Javitt, M.J.; Javitt, J.C. Treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide. Preprints 2020, 2020070453 (doi: 10.20944/preprints202007.0453.v1).

Abstract

Purpose: To assess the clinical safety and possible effectiveness of Vasoactive Intestinal Peptide in the treatment of Acute Respiratory Distress Syndrome (ARDS) related to sepsis. Methods: Under FDA Investigational New Drug clearance, 8 patients with ARDS related to sepsis were treated with 50 pmole/kg/hr – 100 pmole/kg/hr of Vasoactive Intestinal Peptide by intravenous infusion for 12 hours. All patients were on mechanical ventilation and full telemetery. Results: No drug-related serious adverse events were seen. Hypotension was seen in association with two infusions and diarrhea in association with one, but did not necessitate cessation of therapy. Bigeminy was seen in association with one infusion without sequelae. Seven of eight patients demonstrated a successful course during intensive care and were successfully removed from mechanical ventilation and discharged from intensive care. The eighth patient succumbed to purulent secretions in the lungs. Of those who were discharged from the ICU, six demonstrated successful 30 day survival. The seventh died from a cerebral infract at day 30, deemed unrelated to treatment with VIP. Serum levels of Tumor Necrosis Factor α were obtained in 6 patients at baseline and 24 hours and were seen to decrease with treatment in five patients. Conclusions: Initial clinical results of treatment with VIP in patients with ARDS demonstrated a safety profile consistent with previous studies in normal volunteers. The successful clinical course seen in 7 of 8 patients in the setting of an expected 50% survival may suggest that VIP shows promise in the treatment of other infectious conditions that damage the pulmonary epithelium, particularly COVID-19.

Subject Areas

ARDS; VIP; Aviptadil; RLF-100; Acute Respiratory Distress Syndrome; Sepsis

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.